Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies, Inc. Receives Orphan Designation in Europe
Vital Therapies, Inc. Receives Orphan Designation in Europe SAN DIEGO, CA--(Marketwired - Aug 5, 2013) -  Vital Therapies®, Inc., a biopharmaceutical company focused on developing a cell-based therapy targeting the treatment of acute liver failure, today announced that the European
View HTML
Toggle Summary Vital Therapies Inc. adds two new board members
CEO of HeartWare International, Inc. and Former CFO of Amgen Elected to Board of Directors
View HTML
Toggle Summary Vital Therapies, Inc. Enrolls First Patient in VTI-208
Vital Therapies, Inc. Enrolls First Patient in VTI-208 SAN DIEGO, CA--(Marketwired - Apr 4, 2013) - Vital Therapies, Inc., a development-stage biotechnology company focused on developing the first bio-artificial liver for life-threatening acute liver failure, today announced enrollment of the first
View HTML
Toggle Summary Vital Therapies, Inc. Announces Increase in Financing
Muneer A. Satter Elected Co-­‐Chairman of the Board and Lead Director
View HTML
Toggle Summary Vital Therapies Announces $76 Million Financing Staged Financing to Fund Phase 3 Pivotal Clinical Trials of ELAD® in U.S. and E.U.
Orphan Designation Extended to Both Phase 3 Indications in USA; First Acute Alcoholic Hepatitis Trial Now Ready to Enroll in USA
View HTML
Toggle Summary ELAD Phase IIB Data Presented at ATC
Data from Phase 2b Study of ELAD® Presented at the 2012 American Transplant Congress
View HTML
Toggle Summary ELAD Phase IIB Data Presented at ILTS
Data from Phase 2b Study of ELAD® Presented at International Liver Transplant Society Meeting.
View HTML
Toggle Summary Top Ranked Equity Analyst Joins Vital Therapies, Inc.
Top Ranked Equity Analyst Joins Vital Therapies, Inc. SAN DIEGO , March 19, 2012 /PRNewswire/ -- Vital Therapies, Inc., a development stage biotechnology company focused on allogeneic cellular therapy for acute liver failure, today announced that it has appointed Duane Nash , MD, JD, MBA, as
View HTML
Toggle Summary Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD®
Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD ®
View HTML
Toggle Summary Vital Therapies Expands SILVER Trial to Saudi Arabia
Vital Therapies Expands SILVER Trial to Saudi Arabia
View HTML